Work

Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.505

Authors: Otto Metzger, Karla V. Ballman, Jordan Campbell, Minetta C. Liu, Jennifer A. Ligibel, Eveline Chen, Lili Du, W. Fraser Fraser Symmans

Institutions: Alliance for Clinical Trials in Oncology, Dana-Farber Cancer Institute, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Mayo Clinic, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281930290

Cites:

Cited by: 3

Related to: 10